News

Patients on IPX203 received less doses than those on traditional immediate-release carbidopa/levodopa and demonstrated 0.53 more hours of good ON time per day than IR CD/LD.

The executive vice president of the National MS Society discussed the challenges with treating progressive forms of MS, and the accumulating neurodegeneration seen over time. [WATCH TIME: 4 minutes]

Over the 36-month treatment period, nonambulatory patients with SMA treated with apitegromab showed improvements in patient-reported outcomes of daily living and fatigue.

The senior vice president of research at Vaxxinity discussed recently published trial findings on a novel vaccine that targets Alzheimer disease and triggers the production of antibodies against toxic amyloid-ß peptides. [WATCH TIME: 9 minutes]

The phase 2 trial represented the first-ever clinical data to be published of an oral orexin agonist for patients living with narcolepsy type 1.

AOC 1044, an exon 44-targeting agent, holds potential to fill a major unmet need for patients with Duchenne muscular dystrophy, as there are currently there are no approved therapies approved targeting this mutation.

Although the association between genetically predicted insomnia and risk of sepsis was mediated through cardiometabolic risk factors, the data still point to a clear link between the two conditions.

A new platform showed the ability to effectively detect patients with synucleinopathies using serum samples, improving the time and accuracy for diagnosis of specific neurodegenerative diseases such as Parkinson disease.

The associate professor at Yeshiva University and Albert Einstein College of Medicine discussed the significance of motivational interviewing as a means for providers to engage with their patients and the harmful impact of societal stereotypes on individuals with migraine. [WATCH TIME: 5 minutes]

The neurosurgeon at Allegheny Health Network provided perspective on how GammaTile therapy is revolutionizing neurosurgery and post-operative processes of brain tumors.

Foralumab, a therapy designed to bind to T cell receptor, is about to be assessed in phase 2 trials of patients with non-active secondary progressive multiple sclerosis in the third quarter of 2023.

At 6 weeks post-treatment, the patient saw clinical improvements in multiple domains, including autonomic function, vocalization, gross motor skills, and fine motor skills and hand function.

The associate vice president of neuroscience, US Medical Affairs at Eli Lilly discussed the complexities of migraine treatment, highlighting the need to address communication barriers between healthcare providers and patients. [WATCH TIME: 5 minutes]

In a phase 3 study and open-label extension, patients treated with daxibotulinumtoxinA showed significant improvements in their condition, explained by changes on the Toronto Western Spasmodic Torticollis Rating Scale.

The associate professor of pediatrics in neurology and epilepsy at Northwestern University Feinberg School of Medicine discussed the FDA-cleared phase 1/2 trial of an exon 50 skipping therapy to address the specific mutations causing Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]

In addition to showing a safe and tolerable safety profile, patients who underwent the procedure showed a 7-point median improvement on the upper extremity Fugl-Meyer Assessment when used in combination with physical rehabilitation.

The phase 2 clinical trial ACTIVATE investigating BIA 28-6156 for Parkinson disease is currently screening for patients in North America and with the Europe-based study beginning sometime during the third quarter of 2023.

Results indicated a substantial direct effect of air pollution on dementia suggesting that air pollution affects the development of dementia through multiple pathways.

The undergraduate program director at the University of South Carolina discussed the shift in teaching strategies for those in neurology and why more hands-on experience serves students better. [WATCH TIME: 5 minutes]

Stroke of an undetermined cause was associated with acute symptomatic seizures, an effect that was marginally mediated by cerebral microbleeds.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the dilemma of stratifying patients with Parkinson disease based on various criteria and emphasized the need for a consensus on classification. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Patients treated with the neuromodulation device outperformed those on placebo on several key outcomes, including Visual Analog Scale and Migraine-Specific Quality of Life Questionnaire scores.

The associate vice president of neuroscience, US Medical Affairs at Eli Lilly discussed the Think Talk Treat Migraine program which encourages both medical professionals and patients to identify migraine's effects. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology.

The majority of patients with ALS lack a monogenic mutation, with only 15-20% of patients having a disease that is driven and controlled by a single gene.

UB-311 elicited a robust, rapid, and titrated antibody response to amyloid-ß, with an overall 97% responder rate that was maintained by 93% of the cohort by the end of the 78-week study.

Neurology News Network for the week ending August 12, 2023. [WATCH TIME: 3 minutes]

Since it was first discovered in the early 1900s, the therapeutic approaches to treating myasthenia gravis have changed significantly, with several proven treatment options.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 11, 2023.